🔎 Trials Near Me

Home › Cancer (all types) › NCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

RecruitingPhase 2

A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses

Who can join

Ages 18 to 80 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview with evidence that the AjD was instigated by one of the following medical illnesses (e.g., diagnosis, impact, management, recurrence, prognosis): Cancer, ALS, MS, PD or IPF
* Is sufficiently ambulatory and capable of self care as necessary to complete study procedures
* Has normal cognitive function
* Is on stable use of antidepressants or psychotherapy, or is willing to delay use until the end of study
* If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant
* Is willing and able to comply with the conditions and requirements of the study

Exclusion Criteria:

* Has a significant risk of suicide
* Has active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
* Has active or a history of central nervous system malignancy
* Has other medically significant conditions rendering unsuitability for the study
* Has used or will need to use prohibited medications or therapies
* Has a known sensitivity or intolerance to study intervention or potential rescue medications

About the study

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.

What is being tested

Sponsor: Reunion Neuroscience Inc · Participants: 100 · Started: Jul 30, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07002034

Locations in the U.S.

AlabamaUAB, Psychiatry and Behavioral Neurology, Birmingham
ArizonaUniversity of Arizona, Tucson
CaliforniaKadima Neuropsychiatry Institute, San Diego
Providence Medical Foundation, Santa Rosa
ColoradoUniversity of Colorado, Aurora
FloridaUniversity of South Florida, Department of Psychiatry and Behavioral Neuroscience, Tampa
GeorgiaEmory University, Atlanta
HawaiiHawaii Pacific Neuroscience, Honolulu
IllinoisRush University Medical Center, Chicago
University of Chicago Medical Center, Chicago
KansasThe University of Kansas Medical Center, Kansas City
LouisianaLSU Health Shreveport, Shreveport
MarylandSunstone Therapies, PC, Rockville
Sheppard Pratt, Towson
MassachusettsDana Farber Cancer Institute, Boston
University of Massachusetts Chan Medical Center, Worcester
MichiganUniversity of Michigan, Ann Arbor
Henry Ford Health, Novi
NebraskaUniversity of Nebraska Medical Center, Omaha
New MexicoUniversity of New Mexico, School of Medicine, Albuquerque
New YorkRoswell Park Center Institute, Buffalo
NYU Langone Health, New York
North CarolinaUniversity of North Carolina at Chapel Hill, Chapel Hill
OhioCleveland Clinic, Cleveland
The Ohio State University, Department of Psychiatry, Columbus
PennsylvaniaUniversity of Pennsylvania, Philadelphia
TennesseeAlliance for Multispecialty Research Clinical, Knoxville
TexasDell Medical School, University of Texas at Austin, Austin
UtahCedar Clinical Research Inc., Draper
VirginiaUVA Center for Psychiatric Clinical Research, Charlottesville
WashingtonSeattle Neuropsychiatric Treatment Center, Seattle
WisconsinUniversity of Wisconsin at Madison, Madison

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.